Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Arctic Vision Will Start Phase III Trial of Nearsightedness Therapy in China

publication date: Sep 3, 2021

Arctic Vision, a Shanghai ophthalmology company, was approved to start a China Phase III trial of a novel therapy for nearsightedness caused by age-related hardening of the lens. ARVN003 is pilocapine, a known treatment for temporary improvement of nearsightedness, that is administered by Optejet®, a proprietary micro-dosing device. Optejet delivers about 20% of an eye drop, preventing overdosing. In 2020, Arctic acquired China rights to the product from Eyenovia, a US biopharma. Earlier this year, Arctic completed a $100 million B round to expand its in-licensed portfolio. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital